Viridian Therapeutics, Inc. (NASDAQ:VRDN) CEO Acquires $499,262.00 in Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) CEO Stephen F. Mahoney purchased 21,400 shares of the firm’s stock in a transaction dated Friday, September 27th. The stock was purchased at an average cost of $23.33 per share, for a total transaction of $499,262.00. Following the acquisition, the chief executive officer now owns 21,400 shares of the company’s stock, valued at approximately $499,262. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Viridian Therapeutics Trading Down 2.5 %

NASDAQ:VRDN traded down $0.58 during trading hours on Monday, hitting $22.75. The company had a trading volume of 868,145 shares, compared to its average volume of 1,142,569. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.82 and a quick ratio of 15.82. The stock has a 50-day moving average price of $16.99 and a 200 day moving average price of $15.20. The company has a market capitalization of $1.45 billion, a PE ratio of -5.18 and a beta of 1.03. Viridian Therapeutics, Inc. has a 52 week low of $10.93 and a 52 week high of $24.18.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.15). Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.09 million. On average, equities research analysts predict that Viridian Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wolfe Research began coverage on shares of Viridian Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $29.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Viridian Therapeutics in a research note on Monday, July 29th. Oppenheimer reissued an “outperform” rating and issued a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. Royal Bank of Canada restated an “outperform” rating and set a $44.00 price target on shares of Viridian Therapeutics in a research report on Thursday, September 19th. Finally, BTIG Research boosted their price objective on Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.80.

Institutional Investors Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. grew its position in shares of Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock worth $87,000 after buying an additional 799 shares during the period. Principal Financial Group Inc. grew its holdings in Viridian Therapeutics by 9.7% in the first quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after purchasing an additional 1,058 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Viridian Therapeutics by 4.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock valued at $505,000 after purchasing an additional 1,135 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Viridian Therapeutics by 14.7% during the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after purchasing an additional 1,688 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Viridian Therapeutics by 24.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock worth $156,000 after purchasing an additional 2,359 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.